+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
RNA Modifying Agents Market - Global Forecast 2026-2032- Product Image
RNA Modifying Agents Market - Global Forecast 2026-2032- Product Image
Sale

RNA Modifying Agents Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6145522
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The RNA Modifying Agents Market is projected to reach USD 1.54 Billion in 2026. It is expected to continue growing at a CAGR of 12.51%, reaching USD 3.18 Billion by 2032.

RNA Modifying Agents: Executive Overview

RNA modifying agents encompass therapeutic approaches that alter RNA sequence, structure, processing, stability, translation, or degradation. The field includes antisense oligonucleotides, small interfering RNA, messenger RNA technologies, RNA editing, and related delivery systems. Its strategic importance reflects the ability to address targets that may be difficult to influence through conventional small molecules or antibodies, while also creating new requirements for specialized manufacturing, analytical testing, and clinical development.

Platform Convergence Is Reshaping RNA Therapeutics

The landscape is shifting from isolated modality development toward integrated platforms combining sequence design, chemical modification, formulation, and tissue-specific delivery. Advances in conjugation, lipid-based systems, biodegradable materials, and computational design are broadening the range of tissues that can be reached. At the same time, regulatory expectations are becoming more sophisticated around impurities, immunogenicity, durability, off-target effects, and comparability across manufacturing changes. These shifts favor organizations that can connect discovery, delivery, process development, and clinical evidence generation.

Artificial Intelligence Strengthens Design, Delivery, and Development

Artificial intelligence is increasingly useful across the RNA-modifying-agent workflow. Machine-learning tools can support sequence prioritization, prediction of secondary structure, assessment of off-target interactions, optimization of chemical modifications, and identification of delivery formulations. In development, AI can help integrate genomic, transcriptomic, pharmacokinetic, and clinical datasets to refine patient selection and trial design. Its impact remains dependent on the quality and diversity of training data, experimental validation, transparent governance, and controls that prevent algorithmic predictions from being treated as clinical evidence without confirmation.

Regional Dynamics Reflect Research Capacity and Regulatory Readiness

North America combines deep biotechnology infrastructure, advanced translational research, and established pathways for complex therapeutic development. Europe benefits from strong academic networks and coordinated scientific standards, while the European Union places particular emphasis on quality, safety, and data governance. Asia-Pacific is supported by expanding biomanufacturing, clinical research, and innovation capabilities, with Japan, China, South Korea, India, and Australia contributing distinct strengths. Latin America is developing research and production capacity, although access, financing, and specialized infrastructure remain uneven. The Middle East is investing in life-science capabilities and healthcare modernization, while Africa’s opportunity is closely linked to local research capacity, disease priorities, technology transfer, and equitable access.

Economic and Security Blocs Shape Collaboration and Access

ASEAN economies provide a diverse combination of growing healthcare systems, manufacturing potential, and cross-border clinical opportunities, but regulatory alignment remains important. BRICS members contribute substantial scientific, industrial, and patient resources while facing varying levels of infrastructure and policy coordination. The European Union supports collaborative research and common regulatory processes, whereas G7 economies generally provide advanced capital markets, research institutions, and quality systems. GCC countries are strengthening healthcare investment, logistics, and biotechnology agendas. NATO members benefit from extensive scientific and industrial networks, though procurement priorities and technology-security considerations can influence partnerships, supply chains, and data-sharing arrangements.

Country-Level Capabilities Vary Across Science, Manufacturing, and Access

The United States and Canada offer strong translational ecosystems, specialized manufacturing, and sophisticated clinical infrastructure. The United Kingdom, France, Germany, Italy, and Spain contribute established biomedical research, regulatory expertise, and public-health systems within a connected European environment. China, Japan, and South Korea combine advanced research with growing capabilities in biologics, nucleic-acid manufacturing, and delivery technologies. India is important for pharmaceutical production, clinical services, and process engineering. Australia contributes high-quality research and clinical networks. Brazil and Mexico are significant Latin American hubs for healthcare delivery and clinical activity, while Russia retains scientific and industrial capabilities shaped by differing access to international collaboration and inputs. Across these countries, adoption depends on reimbursement, diagnostic capacity, regulatory clarity, and dependable supply chains.

Priorities for Leaders Building Durable RNA Platforms

Industry leaders should prioritize delivery technologies that address specific tissues and disease settings rather than treating RNA chemistry as a standalone advantage. They should establish rigorous analytical controls for identity, potency, impurities, aggregation, stability, and batch comparability, while designing manufacturing networks that reduce dependence on single sources of critical inputs. Partnerships with hospitals, academic centers, diagnostic developers, and regional manufacturers can improve patient identification and implementation. AI programs should be governed through documented validation, human oversight, cybersecurity controls, and prospective testing. Finally, development strategies should incorporate payer evidence, health-system workflows, patient education, and access planning early enough to influence product design and clinical execution.

Methodology: Evidence-Based Synthesis of the RNA Modifying-Agent Landscape

This executive summary uses a structured qualitative synthesis of established scientific, clinical, regulatory, manufacturing, and health-system themes relevant to RNA modifying agents. The assessment organizes evidence by technology shifts, artificial-intelligence applications, regions, economic and security groupings, and specified countries. Interpretation emphasizes recurring signals across peer-reviewed research, public regulatory materials, clinical-trial disclosures, technical publications, and institutional reporting. Claims are framed at the landscape level and avoid market estimates, market sizing, market shares, forecasts, and unsupported company-specific assertions. Regional and country comparisons reflect differences in research capacity, infrastructure, policy, financing, and access conditions.

Conclusion: Execution Will Determine the Next Phase of RNA Innovation

RNA modifying agents are progressing from promising molecular concepts toward increasingly integrated therapeutic platforms. The most important sources of advantage are likely to be tissue-selective delivery, reliable manufacturing, clinically meaningful biomarker strategies, disciplined regulatory execution, and equitable implementation. Artificial intelligence can accelerate these activities, but only when paired with high-quality data and experimental validation. Leaders that connect scientific innovation with operational resilience, regional partnerships, and patient-centered access planning will be best positioned to translate RNA capabilities into durable clinical value.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. RNA Modifying Agents Market, by Agent Class
7.1. Introduction
7.2. Erasers
7.3. Readers
7.4. Writers
8. RNA Modifying Agents Market, by Technology
8.1. Introduction
8.2. Mass Spectrometry
8.3. Microarray
8.4. Sequencing
9. RNA Modifying Agents Market, by Modification Type
9.1. Introduction
9.2. M1A
9.3. M5C
9.4. M6A
9.5. Pseudouridine
10. RNA Modifying Agents Market, by Target Disease
10.1. Introduction
10.2. Genetic Disorders
10.3. Infectious Diseases
10.4. Neurological Disorders
10.5. Oncology
11. RNA Modifying Agents Market, by Application
11.1. Introduction
11.2. Diagnostics
11.3. Research Tools
11.4. Therapeutics
11.4.1. Genetic Disorders
11.4.2. Infectious Diseases
11.4.3. Neurological Disorders
11.4.4. Oncology
12. RNA Modifying Agents Market, by End User
12.1. Introduction
12.2. Academic And Research Institutes
12.3. Contract Research Organizations
12.4. Pharmaceutical And Biotech Companies
13. RNA Modifying Agents Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. RNA Modifying Agents Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. RNA Modifying Agents Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Agilent Technologies, Inc.
17.2. APExBIO Technology LLC
17.3. Bio-Synthesis, Inc.
17.4. Biosynth Ltd.
17.5. BOC Sciences
17.6. Cambridge Isotope Laboratories, Inc.
17.7. Cayman Chemical Company
17.8. Jena Bioscience GmbH
17.9. LGC Limited
17.10. MedChemExpress LLC
17.11. Merck KGaA
17.12. New England Biolabs, Inc.
17.13. Nippon Gene Co., Ltd.
17.14. Selleck Chemicals LLC
17.15. Takara Bio Inc.
17.16. Thermo Fisher Scientific Inc.
17.17. Toronto Research Chemicals Inc.
17.18. Trilink Biotechnologies
17.19. TriLink BioTechnologies, LLC
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global RNA Modifying Agents Market, Years Considered for the Study
FIGURE 2. Global RNA Modifying Agents Market, Research Design
FIGURE 3. Global RNA Modifying Agents Market, Research Framework
FIGURE 4. Global RNA Modifying Agents Market, Data Triangulation
FIGURE 5. Global RNA Modifying Agents Market Size, 2017-2032 (USD Million)
FIGURE 6. Global RNA Modifying Agents Market Size, by Agent Class, 2025 vs 2032 (%)
FIGURE 7. Global RNA Modifying Agents Market Size, by Agent Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global RNA Modifying Agents Market Size, by Technology, 2025 vs 2032 (%)
FIGURE 9. Global RNA Modifying Agents Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global RNA Modifying Agents Market Size, by Modification Type, 2025 vs 2032 (%)
FIGURE 11. Global RNA Modifying Agents Market Size, by Modification Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global RNA Modifying Agents Market Size, by Target Disease, 2025 vs 2032 (%)
FIGURE 13. Global RNA Modifying Agents Market Size, by Target Disease, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global RNA Modifying Agents Market Size, by Application, 2025 vs 2032 (%)
FIGURE 15. Global RNA Modifying Agents Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global RNA Modifying Agents Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global RNA Modifying Agents Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global RNA Modifying Agents Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global RNA Modifying Agents Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global RNA Modifying Agents Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global RNA Modifying Agents Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global RNA Modifying Agents Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global RNA Modifying Agents Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global RNA Modifying Agents Market Segmentation & Coverage
TABLE 2. Global RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 3. Global RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 4. Global Erasers Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Erasers Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Erasers Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Readers Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Readers Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Readers Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Writers Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Writers Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Writers Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 14. Global Mass Spectrometry Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Mass Spectrometry Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Mass Spectrometry Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Microarray Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Microarray Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Microarray Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 24. Global M1A Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global M1A Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global M1A Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global M5C Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global M5C Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global M5C Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global M6A Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global M6A Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global M6A Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Pseudouridine Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Pseudouridine Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Pseudouridine Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 37. Global Genetic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Genetic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Genetic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 50. Global Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Research Tools Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Research Tools Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Research Tools Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Genetic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Genetic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Genetic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 72. Global Academic And Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Academic And Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Academic And Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Pharmaceutical And Biotech Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Pharmaceutical And Biotech Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Pharmaceutical And Biotech Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global RNA Modifying Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific RNA Modifying Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. North America RNA Modifying Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. North America RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 92. North America RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 93. North America RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 94. North America RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 95. North America RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 96. North America RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 97. North America RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. Latin America RNA Modifying Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Latin America RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 100. Latin America RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 101. Latin America RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 102. Latin America RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 103. Latin America RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 104. Latin America RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 105. Latin America RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 106. Europe RNA Modifying Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Europe RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 108. Europe RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 109. Europe RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 110. Europe RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 111. Europe RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 112. Europe RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 113. Europe RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. Middle East RNA Modifying Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Middle East RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 116. Middle East RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 117. Middle East RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 118. Middle East RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 119. Middle East RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 120. Middle East RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 121. Middle East RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. Africa RNA Modifying Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Africa RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 124. Africa RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 125. Africa RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 126. Africa RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 127. Africa RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 128. Africa RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 129. Africa RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. Global RNA Modifying Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. ASEAN RNA Modifying Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. ASEAN RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 133. ASEAN RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 134. ASEAN RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 135. ASEAN RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 136. ASEAN RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 137. ASEAN RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 138. ASEAN RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 139. GCC RNA Modifying Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. GCC RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 141. GCC RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 142. GCC RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 143. GCC RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 144. GCC RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 145. GCC RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 146. GCC RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. European Union RNA Modifying Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. European Union RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 149. European Union RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 150. European Union RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 151. European Union RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 152. European Union RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 153. European Union RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 154. European Union RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. BRICS RNA Modifying Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. BRICS RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 157. BRICS RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 158. BRICS RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 159. BRICS RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 160. BRICS RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. BRICS RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 162. BRICS RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. G7 RNA Modifying Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 164. G7 RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 165. G7 RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 166. G7 RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 167. G7 RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 168. G7 RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 169. G7 RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 170. G7 RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. NATO RNA Modifying Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. NATO RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 173. NATO RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 174. NATO RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 175. NATO RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 176. NATO RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 177. NATO RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 178. NATO RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. Global RNA Modifying Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 180. United States RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 181. United States RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 182. United States RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 183. United States RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 184. United States RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 185. United States RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 186. United States RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 187. United States RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. Canada RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 189. Canada RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 190. Canada RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 191. Canada RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 192. Canada RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 193. Canada RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 194. Canada RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 195. Canada RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. Mexico RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 197. Mexico RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 198. Mexico RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 199. Mexico RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 200. Mexico RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 201. Mexico RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 202. Mexico RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 203. Mexico RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 204. Brazil RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 205. Brazil RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 206. Brazil RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 207. Brazil RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 208. Brazil RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 209. Brazil RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 210. Brazil RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 211. Brazil RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. United Kingdom RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 213. United Kingdom RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 214. United Kingdom RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 215. United Kingdom RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 216. United Kingdom RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 217. United Kingdom RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 218. United Kingdom RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 219. United Kingdom RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. Germany RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 221. Germany RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 222. Germany RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 223. Germany RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 224. Germany RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 225. Germany RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 226. Germany RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 227. Germany RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 228. France RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 229. France RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 230. France RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 231. France RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 232. France RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 233. France RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 234. France RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 235. France RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. Russia RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 237. Russia RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 238. Russia RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 239. Russia RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 240. Russia RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 241. Russia RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 242. Russia RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 243. Russia RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. Italy RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 245. Italy RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 246. Italy RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 247. Italy RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 248. Italy RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 249. Italy RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 250. Italy RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 251. Italy RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 252. Spain RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 253. Spain RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 254. Spain RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 255. Spain RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 256. Spain RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 257. Spain RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 258. Spain RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 259. Spain RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 260. China RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 261. China RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 262. China RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 263. China RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 264. China RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 265. China RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 266. China RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 267. China RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 268. India RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 269. India RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 270. India RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 271. India RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 272. India RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 273. India RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 274. India RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 275. India RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 276. Japan RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 277. Japan RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 278. Japan RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 279. Japan RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 280. Japan RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 281. Japan RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 282. Japan RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 283. Japan RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 284. Australia RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 285. Australia RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 286. Australia RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 287. Australia RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 288. Australia RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 289. Australia RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 290. Australia RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 291. Australia RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 292. South Korea RNA Modifying Agents Market Size, 2017-2032 (USD Million)
TABLE 293. South Korea RNA Modifying Agents Market Size, by Agent Class, 2017-2032 (USD Million)
TABLE 294. South Korea RNA Modifying Agents Market Size, by Technology, 2017-2032 (USD Million)
TABLE 295. South Korea RNA Modifying Agents Market Size, by Modification Type, 2017-2032 (USD Million)
TABLE 296. South Korea RNA Modifying Agents Market Size, by Target Disease, 2017-2032 (USD Million)
TABLE 297. South Korea RNA Modifying Agents Market Size, by Application, 2017-2032 (USD Million)
TABLE 298. South Korea RNA Modifying Agents Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 299. South Korea RNA Modifying Agents Market Size, by End User, 2017-2032 (USD Million)
TABLE 300. Global RNA Modifying Agents Market Share, by Key Player, 2025
TABLE 301. Global RNA Modifying Agents Market, Key Experts

Companies Mentioned

  • Agilent Technologies, Inc.
  • APExBIO Technology LLC
  • Bio-Synthesis, Inc.
  • Biosynth Ltd.
  • BOC Sciences
  • Cambridge Isotope Laboratories, Inc.
  • Cayman Chemical Company
  • Jena Bioscience GmbH
  • LGC Limited
  • MedChemExpress LLC
  • Merck KGaA
  • New England Biolabs, Inc.
  • Nippon Gene Co., Ltd.
  • Selleck Chemicals LLC
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Toronto Research Chemicals Inc.
  • Trilink Biotechnologies
  • TriLink BioTechnologies, LLC

Related Topics

Related Reports

RNA-based Therapeutics - Global Strategic Business Report - Product Image

RNA-based Therapeutics - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 181 Pages
  • Global
From
Friedreich's Ataxia Market Outlook 2026-2034: Market Share, and Growth Analysis by Therapy Type (Disease-modifying Therapies, Gene therapies, Protein-replacement Therapies, RNA-based Therapies, Symptomatic Therapies), Drug Class, Route of Administration, Age Group - Product Image

Friedreich's Ataxia Market Outlook 2026-2034: Market Share, and Growth Analysis by Therapy Type (Disease-modifying Therapies, Gene therapies, Protein-replacement Therapies, RNA-based Therapies, Symptomatic Therapies), Drug Class, Route of Administration, Age Group

  • Report
  • 160 Pages
  • Global
From
RNA Targeting Small Molecules Therapeutics Market Report 2026 - Product Image

RNA Targeting Small Molecules Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
RNA Targeting Small Molecule Drug Discovery Market Report 2026 - Product Image

RNA Targeting Small Molecule Drug Discovery Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.